Trump Announces Price Cuts for Weight Loss Drugs

President Donald Trump announced agreements Thursday with pharmaceutical companies Eli Lilly and Novo Nordisk to reduce prices on popular GLP-1 weight loss drugs, aiming to make treatments more accessible for millions of Americans, particularly those on Medicare and Medicaid.

The deals cover blockbuster medications including Wegovy and Ozempic from Novo Nordisk, and Zepbound and Mounjaro from Eli Lilly. These injectable drugs, which mimic hormones to suppress appetite and manage blood sugar, have seen surging demand since gaining approvals for obesity treatment in recent years. Previously, list prices hovered around $1,000 to $1,350 per month, though negotiated rates with insurers often lowered costs for covered patients.

Under the agreements, Medicare and Medicaid will pay $245 per month for the drugs starting in mid-2026, a significant reduction from current levels. Eligible beneficiaries with obesity and related conditions, such as cardiovascular disease or high blood pressure, will face a $50 monthly copay, officials said. This marks the first time Medicare will routinely cover these therapies specifically for weight loss in high-risk patients, expanding access beyond prior...